Multi-gene cancer panels: what they are and who pays

This page is for anyone thinking about a multigene cancer panel test. It explains what a panel checks, how insurance coverage usually works, and what to ask before the sample is taken.

A multigene test, often just called a panel, checks many genes at once for harmful changes. Instead of checking one suspect gene, it checks a whole list.

NCI explains that panels are often used when a family has no known gene mutation yet. A panel casts a wider net.

Panels come in different sizes. A provider may order one that focuses on genes tied to one type of cancer, or a broad one that checks genes linked to several common cancers.

NCI's position on coverage is simple: health insurance typically covers genetic counseling and genetic tests seen as medically necessary.

The key phrase is "medically necessary." That is an insurance judgment. It depends on things like your own diagnosis, your family history, and what clinical guidelines say for people in your situation.

NCI's practical advice is to talk about costs and coverage with your health care provider and your insurance company before testing. Doing that first is the best way to avoid a surprise bill.

NCI notes that people without insurance can get affordable genetic testing through groups that offer subsidized programs. NCI's Cancer Information Service can help you find them.

Ask about price and coverage before the sample is taken, not when the invoice arrives.

NCI reports that clinical guidelines recommend genetic testing for anyone diagnosed with triple-negative breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer before age 50, metastatic prostate cancer, or male breast cancer.

If one of those applies to you, bring that fact into a coverage conversation. Testing that guidelines recommend stands on firmer ground when a plan decides what counts as necessary.

A wider net can also turn up findings nobody can yet explain.

NCI defines a variant of uncertain significance as a gene change with not enough data to know if it raises cancer risk or not. Such a variant may get reclassified later as researchers learn more.

That has a real effect. NCI says it matters for a person with an uncertain result to stay in touch with the provider who ran the test, so they hear about new findings on that variant.

An uncertain result is not a warning and not an all-clear either. It is an open file. Knowing that ahead of time softens the blow if you get one.

NCI is quite cautious about direct-to-consumer genetic testing. On the FDA-approved test for BRCA variants that you can buy yourself, it states that about 80% of cancer-causing BRCA variants are missed by this approach.

A negative result from a test that checks only a small slice of possible changes may not be reassuring. If this matters to your health decisions, ask your care team or a genetic counselor about testing.

Coverage disputes usually come down to details settled before the sample is even taken. It pays to be a little picky at that stage.

Questions to ask:

• Which lab will run the test, and does my plan cover it?
• Is pre-authorization (approval from your plan ahead of time) needed, and will I hear the answer before testing starts?
• What would the price be if my plan says no?
• Are the counseling visit and the test itself billed separately?

These are reasonable questions to ask your care team.

A panel test can have medical, financial, and family effects. Sorting out the details first is reasonable.